CerSci Therapeutics Inc. — Form D/A
CerSci Therapeutics Inc. of DALLAS, TX, a company, filed a Form D amendment with the SEC on 2020-03-20. The offering totals $12.0M, of which $12.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-03-20
- Form: D/A
- Accession: 0001790478-20-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $12.0M
- Amount sold: $12.0M
- Remaining: $5
- Investors: 24
- Date of first sale: 2019-04-04
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-350547
Issuer
- Name: CerSci Therapeutics Inc.
- CIK: 0001790478
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 17217 WATERVIEW PARKWAY SUITE 1.202, DALLAS, TX, 75252
- Phone: 2143066218
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Tyler Brous | Director | Dallas, TX |
| Pat Confalone | Director | DALLAS, TX |
| Scott Dax | Director | DALLAS, TX |
| Brent Duncan | Director | Durham, NC |
| David Genecov | Director | San Jose, CA |
| John D. Harkey, Jr. | Director | DALLAS, TX |
| David Hitt II | Director | DALLAS, TX |
| Perry Molinoff | Director | DALLAS, TX |
| Dennis Robbins | Director | DALLAS, TX |
| Lucas Rodriguez | Director | Dallas, TX |
| Lucas Rodriguez | Executive Officer | Dallas, TX |
Other filings by this issuer (1)
More